Amarin | AMRN - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 6.72B 1.99B 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amarin USD -2.26M 564K 2025-12
AstraZeneca USD 3.16B 3.95B 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
DBV Technologies USD -47.9M 2.85M 2026-03
GlaxoSmithKline GBP 2.6B 312M 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Novartis USD 4.75B 515M 2026-06